Abstract | OBJECTIVE: METHODS: Pre- and postgadolinium T1 and STIR MR images of the spine were acquired at baseline and at week 24 in patients with AS who participated in a multicenter, randomized, double-blind, placebo-controlled study. Patients were randomly assigned at an 8:3 ratio to receive infusions of infliximab (5 mg/kg) or placebo at weeks 0, 2, and 6 and then every 6 weeks thereafter. MR images were obtained and evaluated independently by 2 readers who were blinded to the treatment allocation and time sequence of the images. RESULTS: A total of 194 patients in the infliximab group and 72 patients in the placebo group had evaluable images at baseline and week 24. About 80% of the patients had at least 1 active spinal lesion at baseline, as assessed by MRI. The improvement in the MRI Activity Score after 6 months was significantly greater in the patients who received infliximab (mean 5.02, median 2.72) than in those who received placebo (mean 0.60, median 0.0) (P < 0.001). Almost complete resolution of spinal inflammation was seen in most patients who received infliximab, irrespective of baseline activity. CONCLUSION:
|
Authors | Jürgen Braun, Robert Landewé, Kay-Geert A Hermann, John Han, Songkai Yan, Paul Williamson, Désirée van der Heijde, ASSERT Study Group |
Journal | Arthritis and rheumatism
(Arthritis Rheum)
Vol. 54
Issue 5
Pg. 1646-52
(May 2006)
ISSN: 0004-3591 [Print] United States |
PMID | 16646033
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Infliximab
|
Topics |
- Adult
- Antibodies, Monoclonal
(therapeutic use)
- Double-Blind Method
- Female
- Humans
- Infliximab
- Magnetic Resonance Imaging
- Male
- Myelitis
(diagnosis, drug therapy)
- Spondylitis, Ankylosing
(diagnosis, drug therapy)
|